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Excessive proliferation and stabilization of themicrotubule
(MT) array in cardiacmyocytes can accompany pathological car-
diac hypertrophy, but themolecular control of these changes re-
mains poorly characterized. In this study, we examinedMT stabi-
lization in two independentmurinemodels of heart failure and
revealed increases in the levels of post-translationallymodified
stableMTs, which were closely associated with STAT3 activation.
To explore themolecular signaling events contributing to control
of the cardiacMTnetwork, we stimulated cardiacmyocytes with
an-adrenergic agonist phenylephrine (PE), and observed in-
creased tubulin content without changes in detyrosinated (glu-
tubulin) stableMTs. In contrast, the hypertrophic interleukin-6
(IL6) family cytokines increased both the glu-tubulin content and
glu-MT density.Whenwe examined a role for ERK in regulating
cardiacMTs, we showed that theMEK/ERK-inhibitor U0126 in-
creased glu-MT density in either control cardiacmyocytes or fol-
lowing exposure to hypertrophic agents. Conversely, expression
of an activatedMEK1mutant reduced glu-tubulin levels. Thus,
ERK signaling antagonizes stabilization of the cardiacMT array.
In contrast, inhibiting either JAK2with AG490, or STAT3 signal-
ing with Stattic or siRNA knockdown, blocked cytokine-stimu-
lated increases in glu-MT density. Furthermore, the expression of
a constitutively active STAT3mutant triggered increased glu-MT
density in the absence of hypertrophic stimulation. Thus, STAT3
activation contributes substantially to cytokine-stimulated
glu-MT changes. Taken together, our results highlight the oppos-
ing actions of STAT3 and ERK pathways in the regulation ofMT
changes associated with cardiacmyocyte hypertrophy.
In cardiac myocytes, the microtubule (MT)5 array com-
prises a major cytoskeletal element. MT organization changes
between phases of assembly/disassembly with either fast (dy-
namic) or slow (stable) kinetics. MT stability can be regulated
through direct association and regulation by numerous pro-
teins such as MT-associated proteins (MAPs), plus-end track-
ing proteins (TIPs) and tubulin-sequestering negative regu-
lators of MT assembly (e.g. stathmins) (1–3). In turn, these
direct modulators of MT stability are regulated by multisite
phosphorylation by various kinases thus linking changes in
MT dynamics with extracellular stimuli (2, 3). Furthermore,
once assembled, tubulin polymers are modified by the addi-
tion of acetyl groups on Lys-40 (acetyl-tubulin) and the re-
versible removal of tyrosine from the -tubulin C terminus
(named glu-tubulin for the penultimate glutamate revealed)
(4, 5). Post-translational modification of tubulin occurs as a
direct function of the time a tubulin heterodimer spends in
the polymerized state and therefore reports on MT age. Al-
though not directly contributing to the stabilization of MTs
per se, these modifications are markers of stabilized MTs that
turnover slowly. In neurons, protein kinases such as the c-Jun
N-terminal kinases and microtubule affinity-regulating ki-
nases have been shown to be key mediators of the MT net-
work (6, 7). In contrast, the signaling events that regulate MTs
in cardiac myocytes are not as well defined.
In addition to well-established roles under physiological
conditions, MT reorganization accompanies the development
of cardiac disease (8). Increased MT numbers correlated with
pathological cardiac hypertrophy induced by pressure over-
load (9, 10) and elevated MT density has been reported in
various models of cardiac disease (11). Significant increases in
MT density and number, as well as increases in MT stabiliza-
tion have been reported during heart failure (12). A causal
link between MT densification/stabilization and cardiac dys-
function was strengthened by observations that MT-targeting
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drugs that enhance MT disassembly could normalize defects
in myocardial contractility in pressure overload hypertrophy
(13). Importantly, MT changes alone were shown to be suffi-
cient to precipitate a reduction in cardiac function (14). Thus,
aberrant MT growth and stabilization can directly contribute
to cardiac disease and promote dysfunction in the hyper-
trophic and failing heart.
Despite the important contribution of MTs to cardiac dis-
ease, the specific upstream signaling events that impact on
MT regulatory proteins are not fully defined. Here we report
the actions of extracellular signal-regulated kinase (ERK) and
a member of the Signal Transducer and Activator of Tran-
scription (STAT) family of transcription factors, STAT3, in
regulating the cardiac myocyte MT array. The ERK family is
activated by a highly conserved signaling cascade and phos-
phorylates several nuclear and cytoplasmic substrates. ERKs
have been implicated in the regulation of hypertrophy (15)
and, in transgenic mice, constitutive cardiac ERK activation is
sufficient to trigger compensated hypertrophy (16). The acti-
vation of STAT3 has been observed in experimental models
of cardiac hypertrophy (17–19) and can occur in parallel with
ERK activation by cytokines such as those for the interleu-
kin-6 (IL6) family (17, 20). A hallmark of active STAT3 is its
tyrosine phosphorylation by Janus kinases (JAKs) followed by
its nuclear translocation and up-regulation of specific gene
targets. Importantly, MT regulatory functions have previously
been ascribed to ERK and STAT3 signaling in non-cardiac
settings (21–23). In our investigation of regulation of cardiac
MTs, we reveal the opposing actions of ERK and STAT3 sig-
naling in MT stabilization.
EXPERIMENTAL PROCEDURES
Reagents—The phospho-STAT3 and the phospho-ERK an-
tibodies were purchased from BD Bioscience and Cell Signal-
ing Technology, respectively. The GAPDH, ERK1/2, and
STAT3 antibodies were purchased from Santa Cruz Biotech-
nology. Oncostatin-M (OSM), AG490, Stattic and U0126
were from Calbiochem. Cy2-/Cy3-conjugated secondary anti-
bodies were obtained fromMillipore and phalloidin-TRITC
fromMolecular Probes. Cell culture serum and reagents were
from Invitrogen-Invitrogen. Leukemic inhibitory factor (LIF),
phenylephrine (PE), nocodazole, anti--tubulin, anti--tubu-
lin, and anti-acetylated tubulin were obtained from Sigma-
Aldrich. The glu-tubulin antibody was purchased from
Chemicon.
Murine Models of Heart Failure—The G203S human car-
diac troponin I (TnI-203) transgenic, R403Q -myosin heavy
chain (MHC-403) knock-out/knock-in and double-mutant
TnI-203/MHC-403 mouse models have been described previ-
ously (24). Dissection of heart tissue and preparation of pro-
tein extracts was performed as described previously (24). In
addition, we examined changes in the hearts of 12-week-old
male FVB/N mice undergoing pressure overload-induced hy-
pertrophy following ascending aortic constriction for 2 weeks
(25). Aortic-banded mice were subdivided into 2 groups: (i)
compensated hypertrophy (ii) decompensated hypertrophy
and heart failure. The delineation of these groups was based
on differences in cardiac function as previously described in
detail (25). In brief, the mice with decompensated hypertro-
phy and heart failure had been exposed to a greater load (aor-
tic pressure gradient) that was associated with a significant
reduction in systolic function compared with mice with com-
pensated hypertrophy, as published previously (Ref. 25; func-
tional and morphological data presented in supplemental Ta-
ble S1). All experiments involving animals were approved by
Institutional Animal Ethics Committees under direction from
the Australian Bureau of Animal Welfare and conform with
the United States NIH Guide for the Care and Use of Labora-
tory Animals.
Neonatal Rat Cardiac Myocyte Culture—Primary normal
cardiac myocytes were isolated from 1–2-day-old Sprague-
Dawley rats as previously described (26). Briefly, ventricular
cells were isolated by collagenase digestion and then pre-
plated to deplete non-myocyte cells. Cardiac myocytes were
then plated on gelatin-coated 60-mm dishes in Dulbecco’s
modified Eagle’s medium/Medium 199 (4:1 v/v) containing
10% (v/v) horse serum, 5% (v/v) fetal calf serum, and penicil-
lin/streptomycin (100 units/ml). The serum was removed af-
ter 18 h, and cells starved for 24 h prior to experimental treat-
ment. Cardiac myocytes were then plated on collagen-coated
dishes or laminin-coated glass coverslips in serum-containing
media. The serum was removed after 18 h, and cells starved
for 24 h prior to experimental treatment and immunoblot/
immunofluorescence analysis.
Protein Lysate Preparation and Immunoblotting—Protein
lysates from cultured cardiac myocytes were lysed in RIPA
buffer (50 mM Tris-HCl, pH 7.3, 150 mM NaCl, 0.1 mM EDTA,
1% (w/v) sodium deoxycholate, 1% (v/v) Triton X-100, 0.2%
(w/v) NaF, and 100 M Na3VO4) supplemented with protease
inhibitors. After lysis, cell debris was removed by centrifuga-
tion. Whole heart protein extracts were prepared by lysing
heart tissue in solubilizing buffer (5 M urea, 2 M thiourea, 2%
CHAPS, 2% sulfobetaine 3–10, 40 mM Tris, 65 mM dithiothre-
itol, and 2 mM tributyl phosphine) and insoluble material
cleared by centrifugation. Protein concentrations were deter-
mined by Bio-Rad Bradford assay and lysates diluted with
Laemmli sample buffer before SDS-PAGE and immunoblot
analysis as previously described (21).
Immunofluorescence Confocal Microscopy and Image
Analysis—MTs in cardiac myocytes were analyzed by immu-
nofluorescence staining with antibodies to -tubulin and
post-translationally modified tubulin. Neonatal rat cardiac
myocytes were plated on laminin-coated glass coverslips over-
night in serum-containing medium. Following experimental
treatments, cells were fixed in 4% (w/v) paraformaldehyde in
PBS, permeabilized with 0.2% (v/v) Triton X-100 in PBS, and
blocked with 10% (v/v) fetal calf serum in PBS. Cells were
then stained with primary antibodies diluted (1:250) in 1%
(w/v) bovine serum albumin (BSA) in PBS and detected with
Cy2-/Cy3- conjugated secondary antibodies (1:500 in 0.1%
(w/v) BSA in PBS). Following mounting, stained cells were
examined by confocal microscopy (Leica TCS SP2 confocal
microscope and laser unit).
Images were compiled and analyzed with Leica Confocal
Software v2.61 (Leica, Germany) and Metamorph analysis
software (Molecular Devices). Microtubule densities (pixels/
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m2) were determined by defining cell borders using phalloi-
din-stained actin filaments as a template. Phalloidin-TRITC
staining of contractile filaments was also used to exclude non-
myocytes, which typically exhibit faint, non-striated linear
stress fibers with actin staining (27). The defined regions were
then transferred to tubulin co-stained images and pixel inten-
sity and cell area (m2) measured (supplemental Fig. S1). A
minimum of 100 cells was measured from 10 randomly se-
lected fields. Microtubule densities (pixels/m2) representa-
tive of three independent experiments (n 3) were expressed
as an average S.E.
STAT3 RNAi—STAT3 Stealth RNAi Duplexes were
obtained from Invitrogen. The double stranded oligoribonucle-
otide sequences targeting STAT3 were target 1: 5-AAGAGG-
UUAUGAAACACCAGAGUGG-3 and 5-CCACUCUGGU-
GUUUCAUAACCUCUU-3, target 2: 5-UUAGGCAUCUG-
ACAGAUGUUGGAGA-3 and 5-UCUCCAACAUCUGUC-
AGAUGCCUAA-3, and target 3: 5-AUAUUGUCUAGCC-
AGACCCAGAACG-3, and 5-CGUUCUGGGUCUGGCU-
AGACAAUAU-3. Stealth RNAi negative control Low GC
Duplex (Invitrogen) was used as a control. RNAi were trans-
fected into cardiac myocytes using LipofectamineTM 2000
according to the manufacturer’s protocol.
Adenovirus Construction and Infection of Cultured Cardiac
Myocytes—The AdMEK-EE virus was generously gifted by J.
Molkentin (University of Cincinnatti). A constitutively active
STAT3 (STAT3-C) mutant, in which the SH2 domain alanine
661 and asparagine 663 were substituted with cysteine resi-
dues (28), was generated by site-directed mutagenesis
(QuikChangeMutagenesis kit, Stratagene). The adenoviral
construct expressing constitutively active STAT3-C (pAd-
STAT3C) was generated using the AdEasy system following
the manufacturer’s instructions (Stratagene) and used to in-
fect primary cardiac myocytes. STAT3-C was subcloned into
the pAdtrack-CMV shuttle vector that expresses GFP from a
cis-promoter. This was recombined with pAdEasy-1 in elec-
tro-competent BJ5183 cells.
AdMEK-EE, AdSTAT3C, and control adenoviruses were
generated by transfection of recombined adenoviral con-
structs into Ad293 cells. Viral particles were expanded, iso-
lated and purified on cesium chloride gradients followed by
dialysis into 3% (w/v) sucrose in PBS. Titers of purified virus
were then determined by colony formation assays before
transduction of cardiac myocytes using a multiplicity of infec-
tion of 50:1. Positive viral transduction of cardiac myocytes
was estimated to be 99% by the cis-promoter driven expres-
sion of GFP from the adenoviral construct.
Statistical Analysis—The statistical significance of observed
differences in immunoblotting (-tubulin, glu-tubulin, or ace-
tubulin) or immunostaining (glu-tubulin) results was deter-
mined by unpaired t test. A p value0.05 was considered
statistically significant.
RESULTS
MT Stabilization Is Observed in Murine Models of Patho-
logical Hypertrophy and Cardiomyopathy—We began by eval-
uating markers of MT stability in a mouse model of pressure
overload hypertrophy. We had previously shown that depend-
ing on the severity of the pressure overload, mice exhibited
either compensated cardiac hypertrophy (maintained systolic
function) or had progressed to decompensated hypertrophy
and failure with depressed contractile function (30% reduc-
tion in systolic function and dilation of ventricular chambers
(supplemental Table S1) subsequent to aortic banding (25).
The levels of -tubulin were increased in pressure overloaded
hearts when compared with control group (sham) (Fig. 1A)
indicating an expansion of the MT network during pressure
overload. We then demonstrated that the levels of acetyl- and
glu-tubulin, that mark stable MTs, were also substantially
elevated in aortic banded mice during both compensated (PO
Comp) and decompensated stages (PO Decomp) (Fig. 1A).
Densitometric analysis of acetyl- and glu-tubulin bands, nor-
malized against changes in -tubulin expression, indicated a
FIGURE 1. Elevatedmarkers of cardiac MT stabilization, phosphorylated
STAT3 and ERK during pressure overload hypertrophy. A, protein ex-
tracts from hearts of 12-week-old mice subjected to aortic banding for 2
weeks, resulting in compensated (PO comp; PO-pressure overload) or de-
compensated hypertrophy (PO decomp), were immunoblotted for phos-
phorylated STAT3 (pY-STAT3), phosphorylated ERK (pT/Y-ERK), STAT3, ERK,
-tubulin, acetyl-, and glu-tubulin. Sham-operated mice were used as the
control group. BC, acetyl-tubulin (B) and glu-tubulin (C) bands were quan-
titated and normalized against -tubulin levels and values expressed as
mean S.E. (**, p 0.01, n 3). D, pY-STAT3 bands were quantitated by
densitometric analysis and normalize against total STAT3. Values represent
mean S.E. (*, p 0.05, n 3).
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significant 3-fold and 2-fold increase, respectively, in pressure
overloaded animals compared with controls (Fig. 1, B and C).
The levels of post-translationally modified tubulin were not
statistically different between the compensated or decompen-
sated hypertrophy groups. These results confirm stabilization
of cardiac MTs during pressure overload.
To investigate signaling mechanisms that could contribute
to MT stabilization, we immunoblotted for phosphorylated
STAT3 and ERK as an indicator of JAK/STAT and ERK
MAPK pathway activation. In response to pressure overload,
cardiac STAT3 phosphorylation was substantially increased
in mice with compensated or decompensated hypertrophy
(Fig. 1A) and correlated well with the elevated levels of post-
translationally modified tubulin. STAT3 protein levels were
also elevated in compensated or decompensated hypertrophy
groups (Fig. 1A). This latter observation is consistent with a
sustained time course of STAT3 activation acting in a positive
feedback loop to increase its own transcription (29). When
the levels of phosphorylated STAT3 were normalized against
total STAT3, we found a significant increase in mice with
pressure overload hypertrophy (Fig. 1D). A single sham oper-
ated animal (lane 3) exhibited a modest increase in phosphor-
ylated STAT3, which correlated with a small increase in glu-
tubulin levels. The reason for this is unclear as the animals in
the sham group were morphologically and functionally indis-
tinguishable and there was no overlap between sham and PO
groups (data not shown). ERK was also found to be activated
in pressure-overloaded mice (Fig. 1A). However, unlike
phosphorylated STAT3, the levels of phosphorylated ERK
between individual mice with pressure overload varied
widely and did not closely match the increases in acetyl
and glu-tubulin (Fig. 1A).
To evaluate the contribution of STAT3 without the compli-
cation of ERK activation, we next looked at MT stabilization
in a double mutation (TnI-203/MHC-403) murine model of
cardiomyopathy that recapitulates a rapid progression to
heart failure observed in human patients (24). A striking fea-
ture of this model was an initial robust activation of cardiac
STAT3, first observed in 10-day-old mice, prior to the onset
of heart failure (24). Importantly, ERK activation was not
found in this mouse model of heart failure (24). We first eval-
uated the levels of -tubulin, glu-, and acetyl-tubulin in the
TnI-203/MHC-403 mice alongside three control groups: non-
transgenic littermates (NTG) and single-mutant mice (TnI-
203 or MHC-403 alone) that did not rapidly develop cardiac
failure. When hearts from 5-day-old mice were examined,
immunoblotting for total -tubulin, glu-tubulin, and acetyl-
tubulin revealed no substantial differences between TnI-203/
MHC-403 mice and the control groups (Fig. 2A). In contrast,
glu-tubulin and acetyl-tubulin were markedly elevated in the
failing hearts from 18 day old TnI-203/MHC-403 mice when
compared with age-matched non-failing hearts from the sin-
gle mutant and NTG control animals (Fig. 2B). Interestingly,
in the failing hearts, total levels of -tubulin levels were not
markedly different from the levels in all control groups (Fig. 2,
A and B).
A more detailed temporal analysis demonstrated glu-tubu-
lin levels were significantly increased in 10, 14, and 18-day-old
TnI-203/MHC-403 mice, compared with the NTG control
group of the same age (Fig. 2, C and D). This coincided with
significant increases in Tyr-705 phosphorylated STAT3 in
10-, 14-, and 18-day-old TnI-203/MHC-403 mice (Fig. 2, E
and F). In addition, the levels of -tubulin and STAT3 ex-
pression were not substantially different between NTG and
TnI-203/MHC-403 groups at any of the time-points stud-
ied (Fig. 2, C and E). A closer kinetic analysis indicated a
substantial increase of phosphorylated STAT3 in 10 day
old TnI-203/MHC-403 mice (supplemental Fig. S2). The
levels of phosphorylated STAT3 increased further in 14-
and 18-day-old TnI-203/MHC-403 mice (supplemental Fig.
S2). Similarly, an increase in glu-tubulin levels was evident
in 10-day-old TnI-203/MHC-403 mice, with considerably
elevated glu-tubulin levels observed in 14- and 18-day-old
animals (supplemental Fig. S2). In comparison, the levels of
phosphorylated STAT3 and glu-tubulin were not increased
greatly by the age of 18 days in the NTG group (supple-
mental Fig. S2).
These results from two independent models of heart failure
show a striking enhancement of markers of the stabilized MT
network. In addition, the close correlation of these changes
with enhanced STAT3 signaling raises the question of the
signaling events and the contribution of STAT3 to the in-
creases in the stable MT subset.
IL6 Family Cytokines Induce MT Stabilization in Cardiac
Myocytes—In subsequent experiments to address the molecu-
lar events that trigger cardiac MT changes, we used primary
cardiac myocytes stimulated with pro-hypertrophic agonists.
We have previously shown that hypertrophy of these cells is
accompanied by an enhanced MT network (27). In this study,
we investigated tubulin changes in cardiac myoyctes following
24 h exposure to the -adrenergic agonist phenylephrine (PE)
or the IL6 family cytokines, LIF or OSM. The increases in the
size of hypertrophic cardiac myocytes (m2) were not sub-
stantially different between the agonists investigated (supple-
mental Fig. S3). We then confirmed by immunoblotting the
increase of -tubulin in cardiac myocytes following 24 h ex-
posure to PE, LIF, or OSM (Fig. 3A). Comparable increases in
-tubulin were also observed (results not shown). To assess
the stable MT population, we next examined glu-tubulin and
acetyl-tubulin and showed elevated levels following 24-h ex-
posure to LIF or OSM (Fig. 3A). After normalizing for -tu-
bulin changes, LIF- and OSM-stimulated a significant in-
crease in glu-tubulin levels compared with control cells (Fig.
3B). However, acetyl-tubulin was not significantly different to
control myocytes (Fig. 3C).
In contrast to cytokine stimulated effects, the levels of post-
translationally modified tubulins were not enhanced by PE
treatment despite increases in total -tubulin levels (Fig. 3A).
Rather, glu-tubulin and acetyl-tubulin levels adjusted for
-tubulin changes were significantly decreased compared
with control cells (Fig. 3, B and C). Furthermore, glu-tubulin
levels were not markedly elevated during short-term treat-
ment (0–8 h) with PE, LIF or OSM (supplemental Fig. S4,
A–C). These results suggest that elevated stable MT markers
observed in IL-6 cytokine-treated myocytes may be the result
of longer term molecular events that actively enhance MT
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stabilization in addition to a general increase in -tubulin ex-
pression. Our observations also indicated that the levels of
glu- and acetyl-tubulin are not correlated to -tubulin levels
in all cases.
Immunofluorescence staining of myocytes confirmed an
increase in the glu-MT subset following 24 h treatment with
LIF or OSM but not PE (Fig. 3D, upper panels). Co-staining
for actin filaments confirmed the reorganization of the sar-
comeres, a hallmark of cardiac myocyte hypertrophy (Fig. 3D,
lower panels). Thus, increases in stable MTs were only in re-
sponse to the IL6-family cytokines, further emphasizing stim-
ulus-specific differences in cardiac MT organization.
We confirmed the stability of the cardiac MT network di-
rectly by exposing control or LIF-treated cardiac myocytes to
FIGURE 2. Increases in cardiac glu-tubulin levels in TnI-203/MHC-403mice coincide with elevated STAT3 phosphorylation. Protein extracts from the
hearts of 5-day-old (A) or 18-day-old (B) non-transgenic (NTG, n 3), TnI-203 (n 3), MHC-403 (n 3), and double mutant TnI-203/MHC-403 mice (n 4)
were immunoblotted for -tubulin as an indicator of the total MT network and post-translationally modified glu- and acetyl-tubulin as indicators of MT sta-
bilization. Immunoblotting for GAPDH indicated equivalent protein loading in all samples. Protein extracts from the hearts of 5, 10, 14, and 18 day old NTG
and TnI-203/MHC-403 mice were immunoblotted for glu-tubulin, -tubulin (C), Tyr-705-phosphorylated STAT3 and STAT3 (E). Glu-tubulin (D) and pY705-
STAT3 (F) bands were quantified by densitometric analysis, normalized for -tubulin and total STAT3 levels, respectively, and values expressed as mean
S.D. (n 3).
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a low dose of a MT-depolymerizing drug, nocodazole (NZ, 2
M, 1 h). We showed a substantial number of MTs remained
after NZ treatment of LIF-stimulated myocytes when com-
pared with the low MT numbers observable in NZ-treated
control myocytes (Fig. 3E). In addition, nocodazole-resistant
MTs in LIF-treated myocytes were substantially longer when
compared with short fragments in the controls (Fig. 3E). In
contrast, a similar analysis in PE-stimulated myocytes treated
with NZ revealed short MT fragments which were more
abundant but comparable in length with MTs in NZ-treated
control cells (supplemental Fig. S5). This indicated that MT
proliferation is increased in response to PE but an increase in
MT stability was not evident. Our studies therefore show in-
creased MT stabilization during IL6 family cytokine stimula-
tion of myocytes and raise the question of the signal transduc-
tion pathways that regulate these MT changes.
ERK Negatively Regulates MT Stabilization—LIF treatment
of normal cardiac myocytes rapidly activates both STAT3 and
FIGURE 3.Hypertrophic agonists stimulate increases in tubulin content and stability in cardiac myocytes. Primary cultures of neonatal rat cardiac
myocytes were treated for 24 h with PE (100 M), LIF (10 ng/ml), OSM (10 ng/ml), or 0.1% (w/v) BSA in PBS as a non-stimulated control (Con). A, protein ly-
sates from treated cardiac myocytes were immunoblotted for -tubulin and post-translationally modified glu- and acetyl-tubulin. Blotting for GAPDH dem-
onstrated equivalent protein loading. Glu-tubulin (B) and acetyl-tubulin (C) bands from immunoblots (n 5) were quantitated by densitometric analysis,
normalized for -tubulin, and expressed as average fold change S.E. Significant changes in glu- and acetyl-tubulin compared with Con are denoted by †,
p 0.05 and *, p 0.05, respectively. D, immunostaining for glu-tubulin (upper panels) and co-staining with TRITC-conjugated phalloidin (lower panels) re-
vealed the stabilized MT network and the organization of contractile actin filaments, respectively. E, Con or LIF-stimulated cardiac myocytes were treated
with nocodazole (NZ, 2 M, 1 h) before immunostaining for -tubulin. Scale bars, 50 m.
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ERK pathways (30). In contrast, PE exposure leads to rapid
activation of the ERK pathway (15) but is not reported to acti-
vate STAT3 directly. We confirmed in normal cardiac myo-
cytes that PE rapidly (15 min) increased ERK phosphorylation
which was sustained over 8 h (supplemental Fig. S6A). In con-
trast, exposure to PE only modestly increased STAT3 phos-
phorylation (supplemental Fig. S6A). LIF or OSM treatment
rapidly (15 min) and markedly increased STAT3 phosphory-
lation (supplemental Fig. S6, B and C). The phosphorylation
of ERK was only modestly increased in response to LIF at 15
min (supplemental Fig. S6B) but was not increased by OSM
treatment at the time points tested (supplemental Fig. S6C).
Furthermore, we observed increased STAT3 phosphorylation
following 24-h stimulation with LIF or OSM, but not PE (sup-
plemental Fig. S6D). Phospho-ERK levels were not signifi-
cantly increased by 24-h treatment with any agonist (supple-
mental Fig. S6D). LIF or OSM therefore stimulated potent
STAT3 activation sustained during the course of cardiac myo-
cyte hypertrophy, prompting us to explore contributions by
STAT3 or ERK to MT stabilization.
We used the MEK-specific inhibitor, U0126, to evaluate a
contribution by ERK signaling in promoting MT stabilization
in cardiac myocytes. We confirmed that U0126 pretreatment
(10 M, 30 min) prevented rapid ERK phosphorylation (15
min) following PE or IL6-family cytokine stimulation whereas
STAT3 Tyr-705 phosphorylation was unaffected (supplemen-
tal Fig. S7A). Following prolonged U0126 exposure (24 h),
ERK activity remained inhibited below basal levels in all treat-
ment groups (Fig. 4A). Although levels of glu-tubulin were
unchanged following PE treatment in cardiac myocytes, glu-
tubulin levels were unexpectedly enhanced in response to PE
treatment in the presence of U0126 (Fig. 4A). Furthermore,
U0126 treatment increased glu-tubulin levels in control
cells or cells exposed to LIF or OSM (Fig. 4A). Similar ob-
servations were made when acetyl-tubulin levels were in-
vestigated (Fig. 4A).
We confirmed these effects with glu-tubulin immunofluo-
rescence staining in cardiac myocytes and estimation of
glu-MT density. After U0126 for 24 h, we observed significant
increases in glu-MT density in the absence of hypertrophic
agonist stimulation (Fig. 4B). U0126 pretreatment further
elevated glu-MT levels during co-treatment with LIF and
OSM (Fig. 4B). In addition, U0126 pretreatment elevated
glu-MT density in PE-treated myocytes even though PE treat-
ment alone did not significantly increase glu-MT density (Fig.
4B). The effects of U0126 exposure on glu-MTs following PE
treatment are shown in representative images (supplemental
Fig. S8).
We next sought to determine the effect of specific activa-
tion of the ERK pathway, through adenoviral-mediated ex-
pression of an activated MEK1 mutant (AdMEK-EE) (16), on
glu-tubulin levels. Whereas cardiac myocytes infected with a
control adenovirus (vector) responded to LIF stimulation with
increased levels of glu-tubulin (Fig. 4C), glu-tubulin was not
detected in unstimulated cardiac myocytes expressing MEK-
EE, nor following cytokine stimulation of MEK-EE expressing
cells (Fig. 4C). We confirmed by immunoblot analysis that the
levels of phosphorylated ERK were elevated in cardiac myo-
cytes expressing MEK-EE but not in control infected cells
(Fig. 4C). Immunoblotting for -tubulin and ERK1/2 revealed
expression levels of total proteins. Taken together, our results
indicate that the ERK pathway negatively regulates the stable
MT subset in cardiac myocytes.
Inhibition of STAT3 Signaling Prevents Cytokine-stimulated
MT Stabilization—We next evaluated the contribution by
STAT3 signaling to MT reorganization through pharmaco-
logical inhibition of JAK, a direct upstream STAT3 activator.
FIGURE 4.MEK/ERK signaling negatively regulates stable MTs in cardiac
myocytes. Cultured cardiac myocytes were pretreated with U0126 (10 M,
30 min) or a vehicle control (0.1% (v/v) DMSO), then stimulated (24 h) with
agonists, PE (100 M), LIF (10 ng/ml), OSM (10 ng/ml), or 0.1% (w/v) BSA in
PBS as a control. A, Protein lysates were then prepared blotted with the in-
dicated antibodies. B, Glu-MTs were immunostained to revealed the stabi-
lized MT network and the density of glu-MTs quantitated by immunofluo-
rescence image analysis and results expressed as an average S.E. (*, p
0.01, #, p 0.05, n 3). C, cardiac myocytes were infected (50 moi) with
adenovirus encoding MEK-EE (AdMEK-EE) or a shuttle vector only control
(vector) before stimulating with LIF (10 ng/ml, 24 h) or equivalent volume of
0.1% BSA (w/v) in PBS. Protein lysates were then prepared and blotted with
the indicated antibodies.
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We showed that AG490 pretreatment inhibited rapid (15
min) STAT3 activation following exposure to LIF or OSM
(supplemental Fig. S7B). AG490 pretreatment also inhibited
the sustained (24 h) STAT3 Tyr-705 phosphorylation stimu-
lated by LIF or OSM (Fig. 5A). Because JAK signaling acti-
vates Shp2/Grb2/Ras pathway to activate ERK as well as
STAT pathways (31), we found that AG490 treatment could
also impact ERK activation stimulated by LIF in cardiac myo-
cytes but did not impact on G-protein-coupled receptor me-
diated activation of ERK stimulated by PE (supplemental Fig.
S7B).
When we looked at post-translationally modified tubulin,
we found that AG490 treatment was sufficient to inhibit LIF-
or OSM-stimulated increases in glu-tubulin and acetyl-tubu-
lin (Fig. 5A), suggesting a role for the JAK/STAT pathway as a
critical positive regulator in promoting stable MT increases.
Furthermore, AG490 did not impact on -tubulin levels in
hypertrophic agonist stimulated myocytes (Fig. 5A) indicating
that the reduction in post-translationally modified tubulin
was not due to reduced tubulin content. Immunofluorescence
staining of the glu-MTs demonstrated that, in the presence of
AG490, glu-MT density was not significantly increased by LIF
or OSM when compared with the control cells (Fig. 5B).
AG490 pretreatment also did not significantly change glu-MT
levels in unstimulated or PE-treated cells. LIF- or OSM-stim-
ulated changes in the glu-MT network in the presence or ab-
sence of AG490 are shown in representative images (supple-
mental Fig. S9). These results reveal a role for JAK signaling in
promoting IL-6 cytokine-induced increases in post-transla-
tionally modified stable MTs.
As AG490 is a JAK-specific inhibitor and attenuates STAT3
activation indirectly, we next utilized a new generation chem-
ical inhibitor, Stattic that selectively disrupts active STAT3
dimers (32). We confirmed that Stattic pretreatment (2 M,
30 min) prevented rapid STAT3 activation by LIF or OSM
(supplemental Fig. S7C). Stattic pretreatment of cardiac myo-
cytes prevented the up-regulation of STAT3 phosphorylation,
glu-tubulin, and acetyl-tubulin levels in response to LIF or
OSM treatment (Fig. 5C). As with AG490, -tubulin levels
were unaltered by Stattic (Fig. 5C). Immunofluorescence
measurements indicated that glu-MT density in hypertrophic
LIF-treated myocytes pretreated with Stattic was not statisti-
cally different to the density in unstimulated myocytes (Fig.
5D). Similarly, Stattic pretreatment prevented increases in
glu-MT density in OSM-treated myocytes (Fig. 5D). Repre-
sentative images show that treatment with Stattic inhibited
LIF- or OSM-stimulated increased stabilization of cardiac MT
array (supplemental Fig. S10).
In addition to its inhibition of STAT3 phosphorylation,
Stattic pretreatment increased the levels of phosphorylated
ERK irrespective of hypertrophic agonist stimulation (supple-
mental Fig. S7C). To evaluate the specific contribution of
FIGURE 5. STAT3 inhibition attenuates IL-6 cytokine stimulated stable MT increases in cardiac myocytes. Cultured cardiac myocytes were pretreated
AG490 (50 M, 30 min) (AB), Stattic (2 M, 30 min) (CD), or a vehicle control (0.1% (v/v) DMSO), then stimulated (24 h) with agonists, PE (100 M), LIF (10
ng/ml), OSM (10 ng/ml), or 0.1% (w/v) BSA in PBS as a control. AC, protein lysates were then prepared blotted with the indicated antibodies. BD, Glu-
MTs were immunostained to revealed the stabilized MT network and the density of glu-MTs quantitated by immunofluorescence image analysis and results
expressed as an average S.E. (*, p 0.01, n 3).
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STAT3 to hypertrophic MT changes without the complica-
tion of ERK activation, we next down-regulated STAT3 levels
specifically using small interfering RNA (siRNA) targeting
STAT3. We first demonstrated that transient transfection of
three distinct STAT3-targeting siRNAs (STAT3 siRNA t1, t2,
t3) specifically decreased STAT3 levels when compared with a
control siRNA or mock-transfected myocytes without siRNA
(Fig. 6A). Importantly, the levels of total and phosphorylated
ERK, as well as levels of GAPDH were not altered by these
STAT3 siRNA treatments (Fig. 6A). In addition, we showed
that LIF and OSM-stimulated STAT3 phosphorylation was
attenuated by STAT3 siRNA while phosphorylated ERK levels
were unaltered (supplemental Fig. S7D). We next investigated
post-translationally modified tubulin and found that STAT3
siRNA prevented LIF or OSM-stimulated increases in glu- or
acetyl-tubulin (Fig. 6B). In contrast, a control siRNA did not
prevent cytokine-stimulated increases in stable-MT markers
(Fig. 6B). Furthermore, -tubulin levels and GAPDH were not
substantially altered by STAT3 siRNA expression (Fig. 6B).
Our results indicate that the specific down-regulation of
STAT3 was sufficient to inhibit IL-6 type cytokine-stimulated
MT changes in hypertrophic cardiac myocytes.
To delineate the effect of STAT3-mediated MT changes
from STAT3 regulation of hypertrophy in general, we looked
at the effect of Stattic on glu-tubulin in LIF-treated hypertro-
phied myocytes. Again, we showed that LIF stimulation (24 h)
increased glu-tubulin levels (Fig. 7A). When STAT3 was then
subsequently inhibited in LIF-stimulated hypertrophied myo-
cytes, a rapid decrease in glu-tubulin levels was observed as
early as 60 min treatment with Stattic (Fig. 7A). Blotting for
phosphorylated STAT3 confirmed that Stattic treatment re-
duced STAT3 Y705 phosphorylation while total STAT3 levels
were not perturbed (Fig. 7A). The effect of Stattic treatment
on LIF-hypertrophied myocytes was similarly shown to re-
duce the numbers of glu-MTs through immunofluorescence
studies (Fig. 7B). Stattic treatment did not alter the hyper-
trophic morphology of contractile sarcomeric units (Fig. 7B).
These findings suggest that STAT3-mediated stabilization of
MTs is distinct from the effect of cytokines on cardiac myo-
cyte hypertrophy and not merely a consequence of cell en-
largement. Together, our studies reveal a requirement for
STAT3 signaling for IL6-family cytokine-induced MT stabili-
zation in cardiac myocytes.
Constitutive STAT3 Activation Is Sufficient to Promote MT
Stabilization—To evaluate whether STAT3 activation is suffi-
cient to trigger increased MT stabilization, we utilized adeno-
viral-mediated expression of a constitutively active mutant of
STAT3 (Ad-STAT3C). This revealed that constitutive STAT3
activity in the absence of hypertrophic agonist treatment was
sufficient to induce an apparent increase in MTs in normal
cardiac myocytes as determined by immunostaining for -tu-
bulin (Fig. 8, compare panels i and iv). Furthermore, STAT3C
expression also induced an increase in glu-MTs in cardiac
myocytes without the requirement for hypertrophic agonist
treatment (Fig. 8, compare panels vii and x). Positive viral
transduction of myocytes was verified to be99% of the cell
population by the inclusion of a cis-promoter driven expres-
sion of GFP in the adenoviral construct. (Fig. 8, panels ii, v,
viii, and xii). Thus, sustained activation of STAT3 was suffi-
cient to trigger MT stabilization in the absence of cytokine
stimulation.
DISCUSSION
Excessive increases in MT density have been shown to im-
pede the movement of contractile filaments and reduce con-
tractile function, leading to detrimental effects in chronic
pressure overload associated end-stage heart failure (8). Our
findings in two independent murine models of heart failure
confirmed an increase in stabilized MTs in hearts with hyper-
trophy and contractile dysfunction. Our observed increase in
MT stabilization in the TnI-203/MHC-403 mice is the first
report of MT changes in a mouse model of familial hyper-
trophic cardiomyopathy. In addition, increased stable-MT
markers were observed in pressure overload mice that had yet
to exhibit contractile deficits (Fig. 1, PO Comp), which sup-
ports the notion that maladaptive reorganization of the car-
diac MT network may precede and contribute to the onset of
heart failure. This is also supported by kinetic analysis in TnI-
203/MHC-403 mice where glu-tubulin increases precede the
onset of severe heart failure. Thus, our findings suggest that
increased stabilization of cardiac MTs is closely associated
with heart failure pathology of different origins.
The increases in post-translationally modified forms of tu-
bulin associated with cardiac hypertrophy in the mouse mod-
els prompted our evaluation of the changes in MTs in cardiac
myocytes as these contractile cells contribute a significant
proportion of protein in the heart. While differences in neo-
FIGURE 6. STAT3 knockdown attenuates increases in post-translation-
ally modified tubulin stimulated by IL-6-type cytokines. A, cultured car-
diac myocytes were transiently transfected with STAT3-targeting siRNAs
(STAT3 siRNA t1, t2, or t3), a non-targeting negative control siRNA (Con
siRNA) or mock-transfected without oligoribonucleotides. At 48 h post-
transfection, protein lysates were prepared and blotted for STAT3, ERK ex-
pression, phosphorylated ERK, and GAPDH as a loading control. B, cardiac
myocytes were transfected with STAT3-targeting siRNA or non-targeting
control siRNA before stimulation with LIF (10 ng/ml, 24 h) or OSM (10 ng/ml,
24 h). Glu-, acetyl-tubulin, and -tubulin levels were then determined by
immunoblotting. GAPH was also blotted as a control for protein loading.
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natal versus adult cardiac myocytes are appreciated, isolated
adult cells have been restricted by a lack of flexibility under
prolonged culture and problematic responses to MT-target-
ing chemical treatments (33). In addition, extensive studies in
neonatal cardiac myocytes have continued to provide new
information on molecular mechanisms involved in adult-on-
set diseases (16, 34–36). Thus, cardiac myocytes isolated from
neonatal animals remains a useful and robust model system
amenable to the experimental manipulation required for de-
tailed mechanistic studies. Importantly, our studies suggest
that the increased levels of post-translationally modified MTs
associated with cardiac disease are regulated by changes in
the activity/expression of molecular regulators of MT stability
in addition to any increases in total tubulin content.
A striking finding of our study has been the opposing ac-
tions of ERK and STAT3 in regulating the MT array in neona-
tal cardiac myocytes. Our attention was initially drawn to
these two signal transduction pathways as each has been im-
plicated in the development of cardiac hypertrophy. In con-
sidering a role for the ERK MAPK pathway, constitutive ERK
activation in transgenic mice has been previously shown to
stimulate hypertrophy that is compensated and maintains
contractile function (16). However, a contribution by ERK
signaling to microtubule changes during cardiac hypertrophy
had not been previously reported. Our findings that MT sta-
bilization is elevated following ERK inhibition and attenuated
by constitutive ERK activation indicates that MEK/ERK sig-
naling may negatively modulate levels of stable MTs and sup-
FIGURE 7. STAT3 inhibition in hypertrophic cardiac myocytes reverses MT stabilization. A, hypertrophy in cultured cardiac myocytes were in-
duced by LIF (10 ng/ml) treatment for 24 h before treatment with Stattic (2 M) for the indicated times. Lysates were then immunoblotted for glu-
tubulin and bands quantitated by densitometric analysis. Values are expressed relative to glu-tubulin levels in untreated control myocytes. Phosphor-
ylated STAT3 and STAT3 expression was also determined by immunoblotting. B, hypertrophic cardiac myocytes induced by LIF (10 ng/ml) treatment
for 24 h was subsequently treated with Stattic (2 M) or and equivalent volume of DMSO for 2 h before immunostaining with glu-tubulin antibody.
Untreated cardiac myocytes were also stained for glu-tubulin as a control (Con). Phalloidin-TRITC staining revealed cardiac myocyte contractile fila-
ments. Scale bar, 20 m.
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ports the notion that multiple mechanisms are involved in
MT reorganization associated with cardiac hypertrophy. As
MT reorganization is specifically linked to cardiac hypertro-
phy associated with contractile dysfunction (13, 37), our find-
ings suggest that stable MTs could be promoted in the ab-
sence or down-regulation of ERK activity and is consistent
with ERK function in promoting cardiac hypertrophy without
contractile deficits. One complication arises with the recent
study reporting modest elevation of glu-tubulin levels in PE-
treated neonatal cardiac myocytes, although this study did not
investigate effects of other hypertrophic stimuli such as the
IL6 family of cytokines or the specific role for the ERK
MAPKs (35).
In contrast to our findings with ERK, our results also indi-
cate that STAT3 signaling is involved in cytokine-induced
increases in MT stability and is sufficient to promote an in-
crease in glu-tubulin in normal cardiac myocytes. From con-
ditional gene knock-out animal studies, the function of car-
diac STAT3 signaling appears to be cardioprotective in
situations of acute cardiac insult (38). The protective actions
of STAT3 have been largely attributed to its regulation of spe-
cific target genes involved in vascularization, antioxidant sta-
tus, and the suppression of apoptosis (39, 40). However, stud-
ies have not adequately addressed the function of STAT3
activation during chronic cardiac disease.
We have previously demonstrated activation of STAT3 in
explanted failing human hearts (41) and recently revealed sus-
tained STAT3 activation in a double mutation mouse model
of familial hypertrophic cardiomyopathy (24). In this study,
we further confirmed robust STAT3 Tyr-705 phosphorylation
in two distinct murine models of heart failure. Importantly,
STAT3 activation preceded the onset of contractile deficits in
both models. This highlights the potential role for STAT3-
mediated events in regulating the development of heart fail-
ure. In contrast, transient activation of STAT3 during pres-
sure overload hypertrophy have been previously reported
(18–20). The differences in the kinetics of STAT3 activation,
compared with the current study, may reflect species specific
effects, differences in surgical methods or the severity of the
aortic banding to induce pressure overload. For example, in a
previous report of transient STAT3 activation following aortic
constriction in rabbits, no reduction in contractile function
(i.e. a decrease in fractional shortening) was observed at 4
weeks post-constriction (18). Furthermore, although maxi-
mum STAT3 activation is rapid and transient in response to
step loading, submaximal levels of STAT3 phosphorylation,
that remain elevated over controls, are observed at the longest
time points (typically 1–2 weeks) investigated in several stud-
ies (19, 20). Indeed, elevated STAT3 phosphorylation has
been reported as long as 9 weeks after aortic constriction in a
murine model of pressure overload hypertrophy (42). Thus,
persistent activation of STAT3 has been observed in several
animal models of pressure overload hypertrophy.
Our results indicate that persistent STAT3 activation is
linked to MT changes associated with cardiac hypertrophy
and suggest that sustained STAT3 activity plays a key role in
the context of heart failure. Indeed, a previous report high-
lighted that persistent STAT3-mediated gene expression
changes induced by angiotensin II contributed to diastolic
dysfunction and cardiac myocyte loss during post-infarction
FIGURE 8. Constitutively active STAT3 is sufficient to promote MT network densification and stabilization. A constitutively active STAT3 mutant
(STAT3C) co-expressed with GFP or the GFP-expressing shuttle vector were transfected into cardiac myocytes by adenoviral transduction (50 moi). Immu-
nofluorescence analysis of the MT network and stabilized MT network were determined by immunostaining for -tubulin (i, iv) and glu-tubulin (vii, x), re-
spectively. Viral transduction of myocytes was confirmed by visualizing GFP fluorescence (ii, v, viii, xi). Cell nuclei were stained with DAPI (iii, vi, ix, xii). Scale
bar, 20 m.
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remodeling of the myocardium (43). More recently, a compel-
ling study demonstrated that dysregulated gp130-STAT3 sig-
naling, characterized by a sustained STAT3 activation kinetic,
was detrimental during cardiac remodeling following myocar-
dial infarction in mice (44). Thus, STAT3 activation in the
heart may not be universally protective. However, STAT3
regulates MT dynamics to control normal cellular processes
in non-myocytes (21, 23). A similar role for STAT3 in con-
trolling MT-driven processes in cardiac myocytes that are
beneficial is also likely. Further investigation to delineate
STAT3-regulated MT functions linked specifically with con-
tractile dysfunction would be prudent.
Another question remains as to how STAT3 activation in-
creases stabilization of MTs. We and others have demon-
strated that, in non-cardiac cells, STAT3 can negatively regu-
late the activity of a key cytoplasmic MT-destabilizing factor,
stathmin, through direct protein-protein interaction to im-
pact on MT dynamics (21, 23). Thus, it would be interesting
to investigate STAT3 binding of stathmin in hypertrophied or
failing hearts in future studies. However, transcriptional regu-
lation of factors that contribute to MT assembly by sustained
STAT3 activity is also likely. Clearly, the precise mechanisms
through which STAT3 modulates the hypertrophic cardiac
MT array warrants further characterization. In summary, our
results have revealed the contrasting functions of ERK and
STAT3 signaling in regulating MT stability in cardiac myo-
cytes. Our findings support further study to determine the
contribution of these mechanisms in regulating MT changes
linked to severe decompensated hypertrophy and subsequent
cardiac failure.
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Supplementary Figure Legends 
 
SUPPLEMENTARY FIGURE 1. Quantitative analysis of MT density in cultured cardiac 
myocytes.  
Cultured cardiac myocytes were treated with LIF (10 ng/ml, 24 h) or 0.1% (w/v) BSA in PBS 
as a control (Con). The myocytes were then fixed, immunostained for glu-tubulin. Staining 
with phalloidin-TRITC revealed contractile actin filaments. Regions of interest (ROI) were 
delineated as individual cardiac myocytes as described in the Materials and Methods. Pixel 
density and cell area (m2) were then quantified to determine glu-MT density (pixels/m2). A 
minimum of 100 cells was measured from 10 randomly selected fields. These images are 
representative of randomly selected fields of cardiac myocytes used for quantitative analysis 
of MT density. Microtubule densities representative of three independent experiments (n=3) 
were expressed as an average  standard error of the mean (SEM). Scale bar = 50 m. 
 
SUPPLEMENTARY FIGURE 2. Temporal analysis of glu-tubulin and phosphorylated 
STAT3 changes in TnI-203/MHC-403 mice.  
A, Protein extracts from the hearts of 5, 10, 14 and 18 day old non-transgenic (NTG) and 
double-mutant TnI-203/MHC-403 mice (n=3) were immunoblotted for glu-tubulin and Y705 
phosphorylated STAT3. B, Glu-tubulin and pY705-STAT3 bands were quantified by 
densitometric analysis and expressed as fold-increases over levels measured in 5 day old 
samples (mean+SD, n=3).  
 
SUPPLEMENTARY FIGURE 3. Hypertrophic agonist stimulated increases in cardiac 
myocyte size.  
Cardiac myocytes cultured on laminin-coated glass coverslips were stimulated for 24 h with 
PE (100 M), LIF (10 ng/ml), OSM (10 ng/ml), or 0.1% (w/v) BSA in PBS as a non-
stimulated control (Con) before fixing and immunofluorescent staining. Cell size (m2) was 
then determined as part of image analysis of MT density as described in “Experimental 
Procedures”. Cell size values are expressed as mean+SE from three independent experiments. 
‘*’ denotes statistical difference (p<0.05) compared to Con sample.   
 
SUPPLEMENTARY FIGURE 4. Short-term hypertrophic agonist treatment does not 
increase glu-tubulin levels in cardiac myocytes.  
Cultured cardiac myocytes were treated (0 - 8 h) with PE (100 M) (A), LIF (10 ng/ml) (B), 
or OSM (10 ng/ml) (C). Protein lysates were prepared and immunoblotted for glu-tubulin and 
-tubulin.  
 
SUPPLEMENTARY FIGURE 5. Nocodazole-resistant MTs in cardiac myocytes treated 
with PE. 
Con or PE-stimulated (100 M) cardiac myocytes were treated with nocodazole (NZ, 2 M, 1 
h) before fixing and immunostaining for -tubulin to reveal the stabilized drug-resistant MT 
network. Scale bar = 50 m. 
 
SUPPLEMENTARY FIGURE 6. Hypertrophic agonists, PE, LIF and OSM, stimulate 
different STAT3 and ERK phosphorylation kinetics.  
Cultured cardiac myocytes were treated (0 - 8 h) with PE (100 M) (A), LIF (10 ng/ml) (B), 
or OSM (10 ng/ml) (C). Protein lysates were prepared and immunoblotted for active, 
phosphorylated STAT3 and ERK using phospho-specific antibodies (pY-STAT3 and pT/pY-
ERK). Total STAT3 and ERK levels were confirmed to be equivalent in the samples. D, 
 
 
Cultured cardiac myocytes were treated for 24 h with PE (100 M), LIF (10 ng/ml), OSM (10 
ng/ml) or 0.1% (w/v) BSA in PBS as a control (Con) before STAT3 and ERK 
phosphorylation and protein levels were determined by immunoblot analysis. 
 
SUPPLEMENTARY FIGURE 7. Inhibition of STAT3 and ERK activation by 
pharmacological inhibitors or RNAi knockdown . 
Cultured cardiac myocytes were pretreated with U0126 (10 M, 30 min) (A), AG490 (50 M, 
30 min) (B), Stattic (2 M, 30 min) (C), or a vehicle control (0.1% [v/v] DMSO). 
Subsequently, myocytes were stimulated (15 min) with PE (100 M), LIF (10 ng/ml), OSM 
(10 ng/ml) or 0.1% (w/v) BSA in PBS as a control (Con). Protein lysates were prepared and 
immunoblotted for pY-STAT3, STAT3, pT/pY-ERK and ERK levels. D, Cardiac myocytes 
were transfected with STAT3 siRNA target 3 or non-targeting control siRNA (Con siRNA) 
before stimulation with LIF (10 ng/ml, 15 min) or OSM (10 ng/ml, 15 min). STAT3 and ERK 
phosphorylation and protein levels were then determined by immunoblot analysis. Identical 
results were obtained with STAT3 siRNA target 1 and STAT3 siRNA target 2 (data not 
shown).  
 
SUPPLEMENTARY FIGURE 8. Representative images of glu-tubulin immunostaining in 
PE- and/or U0126-treated cardiac myocytes. Scale bar = 50 m. 
 
SUPPLEMENTARY FIGURE 9. Representative images of glu-tubulin immunostaining in 
AG490- or DMSO-treated cardiac myocytes subsequently exposed to LIF or OSM. Scale bar 
= 50 m.  
 
SUPPLEMENTARY FIGURE 10. Representative images of glu-tubulin immunostaining in 
Stattic- or DMSO-treated cardiac myocytes subsequently exposed to LIF or OSM. Scale bar = 
50 m. 
 
 
 
 
 
 
 
 
Supplementary Table 1. Functional and morphological analysis of aortic banded mice. 
Mice were subjected to aortic constriction for 1 week before intraperitoneal injection with 
vehicle. After 1 week (ie 2 weeks aortic constriction), echocardiography was performed. Mice 
were then killed and morphological analysis performed. Op, operation; HR, heart rate; IVS, 
interventricular septum thickness; LVPW, left ventricular diastolic posterior wall thickness; 
EDD, left ventricular end-diastolic dimension; ESD, left ventricular end-systolic dimension; 
FS, fractional shortening; EF, ejection fraction; AoPg, aortic pressure gradient; BW, body 
weight; HW, heart weight; LW, lung weight. *p<0.05 vs sham (ANOVA). # - AoPg was 
measured 1 week post-operation.  
 
 
 
 Sham  
(n=6) 
Compensated 
Hypertrophy (n=7) 
Decompensated 
Hypertrophy  
(n=8) 
     BW, g     27.3+0.3 26.2+0.4 26.4+0.6 
      IVS, mm 0.71+0.04 1.02+0.07 1.03+0.04 
     LVPW, mm 0.72+0.03 1.09+0.09* 1.03+0.04 
     EDD, mm 3.50+0.06 3.23+0.15 3.71+0.15 
     ESD, mm 1.61+0.05 1.49+0.15 2.36+0.18* 
     FS, % 54+1 54+4 37+3* 
     EF, % 90+1 89+2 74+4* 
     HR, bpm 584+32 578+13 532+8 
     AoPg, mm Hg# 4+1 25+1* 29+3* 
     HW/BW, mg/g 4.01+0.15 5.69+0.23* 6.71+0.32* 
     LW/BW, mg/g 4.81+0.10 7.31+0.56* 12.62+1.35* 
Suppl. Figure 1. Ng et al. 2010
glu-MTs
actin
Con LIF
gl
u-
tu
bu
lin
ph
al
lo
id
in
pY-STAT3
glu-tubulin
1     2     3    4    5     6     7    8    9   10   11   12
5 days 10 days 14 days 18 days
pY-STAT3
glu-tubulin
1     2     3    4    5     6     7    8    9   10   11   12
5 days 10 days 14 days 18 days
NTG
TnI-203/MHC-403
0
2
4
6
8
10
12
NTG
TnI-203/MHC-403
G
lu
-tu
bu
lin
(fo
ld
 in
cr
ea
se
)
5 10 14 18
days old
NTG
TnI-203/MHC-403
0
4
8
12
16
5 10 14 18
days old
pY
-S
TA
T3
   
   
(fo
ld
 in
cr
ea
se
)
Suppl. Figure 2. Ng et al. 2010
A
B
Suppl. Figure 3. Ng et al. 2010
0
200
400
600
800
1000
1200
1400
1600
1800
C
el
l S
iz
e 
(m
2 )
Con PE LIF OSM
*
*
*
Suppl. Figure 4. Ng et al. 2010
glu-tubulin
0   0.25     1      2        4       8      (h)
LIF (10 ng/ml)
tubulin
glu-tubulin
0   0.25     1      2        4       8   (h)
OSM (10 ng/ml)
tubulin
0   0.25     1      2        4       8   (h)
PE (100 M)
glu-tubulin
tubulin
A
B
C
Suppl. Figure 5. Ng et al. 2010
Con + NZ PE + NZ
tu
bu
lin
Suppl. Figure 6. Ng et al. 2010
B
A
pY-STAT3
STAT3
pT/Y-ERK
ERK
pY-STAT3
STAT3
pT/Y-ERK
ERK
pY-STAT3
STAT3
pT/Y-ERK
ERK
C
pY-STAT3
STAT3
Co
n
PE OS
M
LIF (24 h)
pT/Y-ERK
ERK
D
0   0.25   1     2      4      8   (h)
PE (100 M)
0   0.25  1      2      4      8   (h)
LIF (10 ng/ml)
0   0.25  1    2      4     8   (h)
OSM (10 ng/ml)
Suppl. Figure 7. Ng et al. 2010
C
A
U0126
Con   PE   LIF OSM  Con   PE   LIF  OSM  
DMSO
pY-STAT3
STAT3
pT/Y-ERK
ERK
Con    PE   LIF OSM  Con  PE   LIF  OSM  
StatticDMSO
pY-STAT3
STAT3
pT/Y-ERK
ERK
B
pY-STAT3
STAT3
pT/Y-ERK
ERK
AG490
Con    PE    LIF  OSM  Con   PE    LIF  OSM  
DMSO
D
pY-STAT3
STAT3
pT/Y-ERK
ERK
Con     LIF OSM  Con   LIF  OSM  
STAT3 
siRNA t3Con siRNA
PE + U0126Con + U0126
PE + DMSOCon + DMSO
Suppl. Figure 8. Ng et al. 2010
gl
u-
tu
bu
lin
gl
u-
tu
bu
lin
LIF + DMSO
LIF + AG490 OSM + AG490
OSM + DMSO 
Suppl. Figure 9. Ng et al. 2010
gl
u-
tu
bu
lin
gl
u-
tu
bu
lin
LIF + DMSO
LIF + Stattic OSM + Stattic
OSM + DMSO 
Suppl. Figure 10. Ng et al. 2010
gl
u-
tu
bu
lin
gl
u-
tu
bu
lin
Tsoutsman, Julie R. McMullen, Christopher Semsarian and Marie A. Bogoyevitch
Dominic C. H. Ng, Ivan H. W. Ng, Yvonne Y. C. Yeap, Bahareh Badrian, Tatiana
Stabilization during Cardiac Hypertrophy
Transducer and Activator of Transcription 3 (STAT3) in Regulating Microtubule 
Opposing Actions of Extracellular Signal-regulated Kinase (ERK) and Signal
doi: 10.1074/jbc.M110.128157 originally published online November 5, 2010
2011, 286:1576-1587.J. Biol. Chem. 
  
 10.1074/jbc.M110.128157Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/286/2/1576.full.html#ref-list-1
This article cites 44 references, 25 of which can be accessed free at
 by guest on January 24, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
